|
|
||||||||
Departments of Radiation Oncology, Nuclear Medicine and Surgery, Cross Cancer Institute, Edmonton, Alberta, Canada
Departments of Radiology and Diagnostic Imaging and Surgery and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
Correspondence: For correspondence or reprints contact: J. Donald Chapman, Tumor Biology and Biophysics, Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA 19111.
ABSTRACT
Photodynamic therapy (PDT) is known to produce vascular damage in solid tumors resulting in secondary ischemia and tumor cell death from hypoxia. The oxygenation status of both non-treated and PDT-treated Dunning R3327-AT prostate tumors growing in Fischer X Copenhagen rats was investigated with the novel hypoxic marker, 123I-iodoazomycin arabinoside (IAZA). Both qualitative and quantitative data from planar scintigraphy of anesthetized tumor-bearing rats showed increased retention of 123>I-IAZA in tumors treated with PDT. Tumor perfusion in the same tumors was measured with 99mTc-hexamethylpropyleneamineoxime (HMPAO). Region of interest analyses revealed an inverse correlation between tumor hypoxia measured by 123I-IAZA and tumor perfusion as measured by 99mTc-HMPAO (coefficient of correlation, r = 0.72). Planar images of 2-mm frozen sections from a large tumor showed 123I-IAZA selectively retained in the region that had been treated with PDT. This and other iodinated azomycin nucleosides, labeled with 123I, show promise for monitoring tumor oxygenation status noninvasively and, in particular, for monitoring the effectiveness of interstitial PDT treatments where perfusion shutdown is a major mechanism of tumor response.
This article has been cited by other articles:
![]() |
Z. Xiao, S. Halls, D. Dickey, J. Tulip, and R. B. Moore Fractionated versus Standard Continuous Light Delivery in Interstitial Photodynamic Therapy of Dunning Prostate Carcinomas Clin. Cancer Res., December 15, 2007; 13(24): 7496 - 7505. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Chen, B. W. Pogue, X. Zhou, J. A. O'Hara, N. Solban, E. Demidenko, P. J. Hoopes, and T. Hasan Effect of Tumor Host Microenvironment on Photodynamic Therapy in a Rat Prostate Tumor Model Clin. Cancer Res., January 15, 2005; 11(2): 720 - 727. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-W. Wang, M. E. Putt, M. J. Emanuele, D. B. Shin, E. Glatstein, A. G. Yodh, and T. M. Busch Treatment-Induced Changes in Tumor Oxygenation Predict Photodynamic Therapy Outcome Cancer Res., October 15, 2004; 64(20): 7553 - 7561. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Britz-Cunningham and S. J. Adelstein Molecular Targeting with Radionuclides: State of the Science J. Nucl. Med., December 1, 2003; 44(12): 1945 - 1961. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. V. Iyer, P. T. Haynes, R. F. Schneider, B. Movsas, and J. D. Chapman Marking Hypoxia in Rat Prostate Carcinomas with {beta}-D-[125I]Azomycin Galactopyranoside and [99mTc]HL-91: Correlation with Microelectrode Measurements J. Nucl. Med., February 1, 2001; 42(2): 337 - 344. [Abstract] [Full Text] |
||||
![]() |
T. M. Busch, S. M. Hahn, S. M. Evans, and C. J. Koch Depletion of Tumor Oxygenation during Photodynamic Therapy: Detection by the Hypoxia Marker EF3 [2-(2-Nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide] Cancer Res., May 1, 2000; 60(10): 2636 - 2642. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |